Provided herein is technology relating to antagonists that inhibit, reduce, or minimize the interaction of integrin associated protein (IAP) with Src homology 2 (SH2) domain-containing protein tyrosine phosphatase substrate 1 (SHPS1) and particularly, but not exclusively, to compositions comprising such antagonists and methods of treatment comprising administering such antagonists.
